PTJ
SNDX icon

Paul Tudor Jones’s Syndax Pharmaceuticals SNDX Stock Holding History

Paul Tudor Jones’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,300
Closed -$1.01M – 4224
2025
Q4 		$1.01M Buy
+48,300
New +$843K ﹤0.01% 2265

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Paul Tudor Jones's SNDX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 69,059 shares — an estimated $1.61M sold.

Paul Tudor Jones first reported a position in SNDX in Q4 2022 and held it in 10 quarters. The position peaked at $1.61M in Q1 2026. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Paul Tudor Jones reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 69,059 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.61M.
  • Paul Tudor Jones first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Paul Tudor Jones's Syndax Pharmaceuticals position peaked at $1.61M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.